Teleflex: UroLift 2
Teleflex (NYSE:TFX) is expected to launch its UroLift 2 System in 2021, according to a January investor presentation.
The UroLift 2 is the second generation of its UroLift, a minimally invasive, in-office treatment designed for rapid relief and recovery from symptoms of benign prostatic hyperplasia, or enlarged prostate.
While the UroLift implant design remains the same, UroLift 2 has multiple cartridges per handle for greater ease of use and to reduce medical waste. The first generation has only one cartridge.
The device works by delivering the implant during a transurethral outpatient procedure to relieve prostate obstruction and open the urethra directly without cutting, heating or removing prostate tissue.
Teleflex has a number of catheter-based innovations in its pipeline, including the Weck AutoNedo HOL large clip applier and the Wattson.
